A	O
prospective	B:C0033522
study	I:C0033522
of	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
outcomes	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
managed	O
by	O
active	O
surveillance	I:C1827061
or	O
radiation	O
therapy	I:C1522449
.	O

A	O
prospective	O
study	I:C0033522
of	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
outcomes	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	B:C0376358
cancer	I:C0376358
managed	O
by	O
active	O
surveillance	I:C1827061
or	O
radiation	O
therapy	I:C1522449
.	O

A	O
prospective	O
study	I:C0033522
of	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
outcomes	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
managed	O
by	O
active	B:C1827061
surveillance	I:C1827061
or	O
radiation	O
therapy	I:C1522449
.	O

A	O
prospective	O
study	I:C0033522
of	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
outcomes	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
managed	O
by	O
active	O
surveillance	I:C1827061
or	O
radiation	B:C1522449
therapy	I:C1522449
.	O

Patients	O
with	O
low	O
-	O
risk	O
prostate	B:C0376358
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
often	O
have	O
excellent	O
oncologic	O
outcomes	O
.	O

Patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
(	O
prostate	B:C0376358
cancer	I:C0376358
)	O
often	O
have	O
excellent	O
oncologic	O
outcomes	O
.	O

Patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
often	O
have	O
excellent	O
oncologic	B:C0027651
outcomes	O
.	O

However	O
,	O
treatment	B:C0087111
with	O
curative	O
intent	O
can	O
lead	O
to	O
decrements	O
in	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
.	O

Patients	O
treated	B:C0332293
with	I:C0332293
radical	O
prostatectomy	I:C0194810
have	O
been	O
shown	O
to	O
suffer	O
declines	O
in	O
urinary	O
and	O
sexual	O
HRQoL	O
as	O
compared	O
to	O
those	O
managed	O
with	O
active	O
surveillance	I:C1827061
(	O
active	O
surveillance	I:C1827061
)	O
.	O

Patients	O
treated	O
with	I:C0332293
radical	B:C0194810
prostatectomy	I:C0194810
have	O
been	O
shown	O
to	O
suffer	O
declines	O
in	O
urinary	O
and	O
sexual	O
HRQoL	O
as	O
compared	O
to	O
those	O
managed	O
with	O
active	O
surveillance	I:C1827061
(	O
active	O
surveillance	I:C1827061
)	O
.	O

Patients	O
treated	O
with	I:C0332293
radical	O
prostatectomy	I:C0194810
have	O
been	O
shown	O
to	O
suffer	O
declines	O
in	O
urinary	O
and	O
sexual	B:C0009253
HRQoL	O
as	O
compared	O
to	O
those	O
managed	O
with	O
active	O
surveillance	I:C1827061
(	O
active	O
surveillance	I:C1827061
)	O
.	O

Patients	O
treated	O
with	I:C0332293
radical	O
prostatectomy	I:C0194810
have	O
been	O
shown	O
to	O
suffer	O
declines	O
in	O
urinary	O
and	O
sexual	O
HRQoL	O
as	O
compared	O
to	O
those	O
managed	O
with	O
active	B:C1827061
surveillance	I:C1827061
(	O
active	O
surveillance	I:C1827061
)	O
.	O

Patients	O
treated	O
with	I:C0332293
radical	O
prostatectomy	I:C0194810
have	O
been	O
shown	O
to	O
suffer	O
declines	O
in	O
urinary	O
and	O
sexual	O
HRQoL	O
as	O
compared	O
to	O
those	O
managed	O
with	O
active	O
surveillance	I:C1827061
(	O
active	B:C1827061
surveillance	I:C1827061
)	O
.	O

Similarly	O
,	O
patients	O
treated	B:C0332293
with	I:C0332293
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
(	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
)	O
are	O
hypothesized	O
to	O
experience	O
greater	O
declines	O
in	O
bowel	O
HRQoL	O
.	O

Similarly	O
,	O
patients	O
treated	O
with	I:C0332293
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
(	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
)	O
are	O
hypothesized	O
to	O
experience	O
greater	O
declines	O
in	O
bowel	O
HRQoL	O
.	O

Similarly	O
,	O
patients	O
treated	O
with	I:C0332293
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
(	O
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
)	O
are	O
hypothesized	O
to	O
experience	O
greater	O
declines	O
in	O
bowel	O
HRQoL	O
.	O

Similarly	O
,	O
patients	O
treated	O
with	I:C0332293
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
(	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
)	O
are	O
hypothesized	O
to	O
experience	O
greater	O
declines	O
in	O
bowel	B:C0021853
HRQoL	O
.	O

As	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
(	O
HRQoL	O
)	O
concerns	O
are	O
paramount	O
when	O
selecting	O
among	O
treatment	B:C0087111
options	O
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
this	O
study	O
examined	O
HRQoL	O
outcomes	O
in	O
men	O
undergoing	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
as	O
compared	O
to	O
active	O
surveillance	I:C1827061
in	O
a	O
prospective	O
,	O
racially	O
diverse	O
cohort	O
.	O

As	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
(	O
HRQoL	O
)	O
concerns	O
are	O
paramount	O
when	O
selecting	O
among	O
treatment	O
options	O
for	O
low	O
-	O
risk	O
prostate	B:C0376358
cancer	I:C0376358
,	O
this	O
study	O
examined	O
HRQoL	O
outcomes	O
in	O
men	O
undergoing	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
as	O
compared	O
to	O
active	O
surveillance	I:C1827061
in	O
a	O
prospective	O
,	O
racially	O
diverse	O
cohort	O
.	O

As	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
(	O
HRQoL	O
)	O
concerns	O
are	O
paramount	O
when	O
selecting	O
among	O
treatment	O
options	O
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
this	O
study	B:C2603343
examined	O
HRQoL	O
outcomes	O
in	O
men	O
undergoing	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
as	O
compared	O
to	O
active	O
surveillance	I:C1827061
in	O
a	O
prospective	O
,	O
racially	O
diverse	O
cohort	O
.	O

As	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
(	O
HRQoL	O
)	O
concerns	O
are	O
paramount	O
when	O
selecting	O
among	O
treatment	O
options	O
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
this	O
study	O
examined	B:C0332128
HRQoL	O
outcomes	O
in	O
men	O
undergoing	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
as	O
compared	O
to	O
active	O
surveillance	I:C1827061
in	O
a	O
prospective	O
,	O
racially	O
diverse	O
cohort	O
.	O

As	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
(	O
HRQoL	O
)	O
concerns	O
are	O
paramount	O
when	O
selecting	O
among	O
treatment	O
options	O
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
this	O
study	O
examined	O
HRQoL	O
outcomes	O
in	O
men	O
undergoing	O
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
as	O
compared	O
to	O
active	O
surveillance	I:C1827061
in	O
a	O
prospective	O
,	O
racially	O
diverse	O
cohort	O
.	O

As	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
(	O
HRQoL	O
)	O
concerns	O
are	O
paramount	O
when	O
selecting	O
among	O
treatment	O
options	O
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
this	O
study	O
examined	O
HRQoL	O
outcomes	O
in	O
men	O
undergoing	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
as	O
compared	O
to	O
active	B:C1827061
surveillance	I:C1827061
in	O
a	O
prospective	O
,	O
racially	O
diverse	O
cohort	O
.	O

As	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
(	O
HRQoL	O
)	O
concerns	O
are	O
paramount	O
when	O
selecting	O
among	O
treatment	O
options	O
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
this	O
study	O
examined	O
HRQoL	O
outcomes	O
in	O
men	O
undergoing	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
as	O
compared	O
to	O
active	O
surveillance	I:C1827061
in	O
a	O
prospective	O
,	O
racially	O
diverse	O
cohort	B:C0599755
.	O

A	O
prospective	B:C0033522
study	I:C0033522
of	O
HRQoL	O
in	O
patients	O
with	O
prostate	O
cancer	I:C0376358
enrolled	O
in	O
the	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
(	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
)	O
Multicenter	O
National	I:C0242356
Database	I:C0242356
was	O
initiated	O
in	O
2007	O
.	O

A	O
prospective	O
study	I:C0033522
of	O
HRQoL	O
in	O
patients	O
with	O
prostate	B:C0376358
cancer	I:C0376358
enrolled	O
in	O
the	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
(	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
)	O
Multicenter	O
National	I:C0242356
Database	I:C0242356
was	O
initiated	O
in	O
2007	O
.	O

A	O
prospective	O
study	I:C0033522
of	O
HRQoL	O
in	O
patients	O
with	O
prostate	O
cancer	I:C0376358
enrolled	O
in	O
the	O
Center	B:C0683939
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
(	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
)	O
Multicenter	O
National	I:C0242356
Database	I:C0242356
was	O
initiated	O
in	O
2007	O
.	O

A	O
prospective	O
study	I:C0033522
of	O
HRQoL	O
in	O
patients	O
with	O
prostate	O
cancer	I:C0376358
enrolled	O
in	O
the	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
(	O
Center	B:C0683939
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
)	O
Multicenter	O
National	I:C0242356
Database	I:C0242356
was	O
initiated	O
in	O
2007	O
.	O

A	O
prospective	O
study	I:C0033522
of	O
HRQoL	O
in	O
patients	O
with	O
prostate	O
cancer	I:C0376358
enrolled	O
in	O
the	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
(	O
Center	O
for	I:C0683939
Prostate	I:C0683939
Disease	I:C0683939
Research	I:C0683939
)	O
Multicenter	B:C0242356
National	I:C0242356
Database	I:C0242356
was	O
initiated	O
in	O
2007	O
.	O

The	O
current	O
study	B:C2603343
included	O
patients	O
diagnosed	O
through	O
April	O
2014	O
.	O

The	O
current	O
study	O
included	O
patients	O
diagnosed	B:C1704656
through	O
April	O
2014	O
.	O

HRQoL	O
was	O
assessed	O
with	O
the	O
Expanded	B:C3810535
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
(	O
Expanded	O
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
)	O
and	O
the	O
Medical	O
Outcomes	I:C0451287
Study	I:C0451287
Short	I:C0451287
Form	I:C0451287
(	O
SF	O
-	I:C0451287
36	I:C0451287
)	O
.	O

HRQoL	O
was	O
assessed	O
with	O
the	O
Expanded	O
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
(	O
Expanded	B:C3810535
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
)	O
and	O
the	O
Medical	O
Outcomes	I:C0451287
Study	I:C0451287
Short	I:C0451287
Form	I:C0451287
(	O
SF	O
-	I:C0451287
36	I:C0451287
)	O
.	O

HRQoL	O
was	O
assessed	O
with	O
the	O
Expanded	O
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
(	O
Expanded	O
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
)	O
and	O
the	O
Medical	B:C0451287
Outcomes	I:C0451287
Study	I:C0451287
Short	I:C0451287
Form	I:C0451287
(	O
SF	O
-	I:C0451287
36	I:C0451287
)	O
.	O

HRQoL	O
was	O
assessed	O
with	O
the	O
Expanded	O
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
(	O
Expanded	O
Prostate	I:C3810535
Cancer	I:C3810535
Index	I:C3810535
Composite	I:C3810535
)	O
and	O
the	O
Medical	O
Outcomes	I:C0451287
Study	I:C0451287
Short	I:C0451287
Form	I:C0451287
(	O
SF	B:C0451287
-	I:C0451287
36	I:C0451287
)	O
.	O

Temporal	O
changes	O
in	O
HRQoL	O
were	O
compared	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	B:C0376358
cancer	I:C0376358
managed	O
on	O
active	O
surveillance	I:C1827061
vs.	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
at	O
baseline	O
,	O
1-	O
,	O
2	O
-	O
,	O
and	O
3	O
years	O
post	O
-	O
prostate	O
cancer	I:C0376358
diagnosis	O
.	O

Temporal	O
changes	O
in	O
HRQoL	O
were	O
compared	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
managed	O
on	O
active	B:C1827061
surveillance	I:C1827061
vs.	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
at	O
baseline	O
,	O
1-	O
,	O
2	O
-	O
,	O
and	O
3	O
years	O
post	O
-	O
prostate	O
cancer	I:C0376358
diagnosis	O
.	O

Temporal	O
changes	O
in	O
HRQoL	O
were	O
compared	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
managed	O
on	O
active	O
surveillance	I:C1827061
vs.	O
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
at	O
baseline	O
,	O
1-	O
,	O
2	O
-	O
,	O
and	O
3	O
years	O
post	O
-	O
prostate	O
cancer	I:C0376358
diagnosis	O
.	O

Temporal	O
changes	O
in	O
HRQoL	O
were	O
compared	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
managed	O
on	O
active	O
surveillance	I:C1827061
vs.	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
at	O
baseline	O
,	O
1-	O
,	O
2	O
-	O
,	O
and	O
3	O
years	O
post	O
-	O
prostate	B:C0376358
cancer	I:C0376358
diagnosis	O
.	O

Temporal	O
changes	O
in	O
HRQoL	O
were	O
compared	O
for	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
managed	O
on	O
active	O
surveillance	I:C1827061
vs.	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
at	O
baseline	O
,	O
1-	O
,	O
2	O
-	O
,	O
and	O
3	O
years	O
post	O
-	O
prostate	O
cancer	I:C0376358
diagnosis	B:C0011900
.	O

Longitudinal	B:C0023981
patterns	I:C0023981
were	O
modeled	O
using	O
linear	O
regression	O
models	O
fitted	O
with	O
generalized	O
estimating	O
equations	O
(	O
GEE	O
)	O
,	O
adjusting	O
for	O
baseline	O
HRQoL	O
,	O
demographic	O
,	O
and	O
clinical	O
patient	O
characteristics	O
.	O

Longitudinal	O
patterns	I:C0023981
were	O
modeled	O
using	O
linear	O
regression	O
models	O
fitted	O
with	O
generalized	O
estimating	O
equations	O
(	O
GEE	O
)	O
,	O
adjusting	O
for	O
baseline	O
HRQoL	O
,	O
demographic	B:C0011289
,	O
and	O
clinical	O
patient	O
characteristics	O
.	O

Of	O
the	O
499	O
eligible	O
patients	O
with	O
low	O
-	O
risk	O
prostate	B:C0376358
cancer	I:C0376358
,	O
103	O
(	O
21	O
%	O
)	O
selected	O
active	O
surveillance	I:C1827061
and	O
60	O
(	O
12	O
%	O
)	O
were	O
treated	O
with	I:C0332293
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
.	O

Of	O
the	O
499	O
eligible	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
103	O
(	O
21	O
%	O
)	O
selected	O
active	B:C1827061
surveillance	I:C1827061
and	O
60	O
(	O
12	O
%	O
)	O
were	O
treated	O
with	I:C0332293
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
.	O

Of	O
the	O
499	O
eligible	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
103	O
(	O
21	O
%	O
)	O
selected	O
active	O
surveillance	I:C1827061
and	O
60	O
(	O
12	O
%	O
)	O
were	O
treated	B:C0332293
with	I:C0332293
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
.	O

Of	O
the	O
499	O
eligible	O
patients	O
with	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
,	O
103	O
(	O
21	O
%	O
)	O
selected	O
active	O
surveillance	I:C1827061
and	O
60	O
(	O
12	O
%	O
)	O
were	O
treated	O
with	I:C0332293
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
.	O

Demographic	O
characteristics	O
of	O
the	O
treatment	B:C0087111
groups	O
were	O
similar	O
,	O
though	O
a	O
greater	O
proportion	O
of	O
patients	O
in	O
the	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
group	O
were	O
African	O
American	I:C0085756
(	O
P	O
=	O
0.0003	O
)	O
.	O

Demographic	O
characteristics	O
of	O
the	O
treatment	O
groups	B:C1257890
were	O
similar	O
,	O
though	O
a	O
greater	O
proportion	O
of	O
patients	O
in	O
the	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
group	O
were	O
African	O
American	I:C0085756
(	O
P	O
=	O
0.0003	O
)	O
.	O

Demographic	O
characteristics	O
of	O
the	O
treatment	O
groups	O
were	O
similar	O
,	O
though	O
a	O
greater	O
proportion	O
of	O
patients	O
in	O
the	O
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
group	O
were	O
African	O
American	I:C0085756
(	O
P	O
=	O
0.0003	O
)	O
.	O

Demographic	O
characteristics	O
of	O
the	O
treatment	O
groups	O
were	O
similar	O
,	O
though	O
a	O
greater	O
proportion	O
of	O
patients	O
in	O
the	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
group	B:C1257890
were	O
African	O
American	I:C0085756
(	O
P	O
=	O
0.0003	O
)	O
.	O

Demographic	O
characteristics	O
of	O
the	O
treatment	O
groups	O
were	O
similar	O
,	O
though	O
a	O
greater	O
proportion	O
of	O
patients	O
in	O
the	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
group	O
were	O
African	B:C0085756
American	I:C0085756
(	O
P	O
=	O
0.0003	O
)	O
.	O

At	O
baseline	O
,	O
both	O
treatment	B:C0087111
groups	O
reported	O
comparable	O
HRQoL	O
.	O

At	O
baseline	O
,	O
both	O
treatment	O
groups	B:C1257890
reported	O
comparable	O
HRQoL	O
.	O

external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
patients	O
experienced	O
significantly	O
worse	O
bowel	O
function	I:C0011135
and	O
bother	O
at	O
1	O
year	O
(	O
adjusted	O
mean	O
score	O
:	O
87	O
vs.	O
95	O
,	O
P	O
=	O
0.001	O
and	O
89	O
vs.	O
95	O
,	O
P	O
=	O
0.008	O
,	O
respectively	O
)	O
and	O
2	O
years	O
(	O
87	O
vs.	O
93	O
,	O
P	O
=	O
0.007	O
and	O
87	O
vs.	O
96	O
,	O
P	O
=	O
0.002	O
,	O
respectively	O
)	O
compared	O
to	O
patients	O
managed	O
on	O
active	O
surveillance	I:C1827061
.	O

external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
patients	O
experienced	O
significantly	O
worse	O
bowel	B:C0011135
function	I:C0011135
and	O
bother	O
at	O
1	O
year	O
(	O
adjusted	O
mean	O
score	O
:	O
87	O
vs.	O
95	O
,	O
P	O
=	O
0.001	O
and	O
89	O
vs.	O
95	O
,	O
P	O
=	O
0.008	O
,	O
respectively	O
)	O
and	O
2	O
years	O
(	O
87	O
vs.	O
93	O
,	O
P	O
=	O
0.007	O
and	O
87	O
vs.	O
96	O
,	O
P	O
=	O
0.002	O
,	O
respectively	O
)	O
compared	O
to	O
patients	O
managed	O
on	O
active	O
surveillance	I:C1827061
.	O

external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
patients	O
experienced	O
significantly	O
worse	O
bowel	O
function	I:C0011135
and	O
bother	O
at	O
1	O
year	O
(	O
adjusted	O
mean	O
score	O
:	O
87	O
vs.	O
95	O
,	O
P	O
=	O
0.001	O
and	O
89	O
vs.	O
95	O
,	O
P	O
=	O
0.008	O
,	O
respectively	O
)	O
and	O
2	O
years	O
(	O
87	O
vs.	O
93	O
,	O
P	O
=	O
0.007	O
and	O
87	O
vs.	O
96	O
,	O
P	O
=	O
0.002	O
,	O
respectively	O
)	O
compared	O
to	O
patients	O
managed	O
on	O
active	B:C1827061
surveillance	I:C1827061
.	O

In	O
contrast	O
to	O
those	O
on	O
active	B:C1827061
surveillance	I:C1827061
,	O
more	O
than	O
half	O
the	O
number	O
of	O
patients	O
who	O
received	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
experienced	O
a	O
decline	O
in	O
bowel	O
function	I:C0011135
(	O
52	O
%	O
vs.	O
17	O
%	O
,	O
p=0.003	O
)	O
and	O
bother	O
(	O
52	O
%	O
vs.	O
15	O
%	O
,	O
P	O
=	O
0.002	O
)	O
from	O
baseline	O
to	O
1	O
year	O
.	O

In	O
contrast	O
to	O
those	O
on	O
active	O
surveillance	I:C1827061
,	O
more	O
than	O
half	O
the	O
number	O
of	O
patients	O
who	O
received	O
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
experienced	O
a	O
decline	O
in	O
bowel	O
function	I:C0011135
(	O
52	O
%	O
vs.	O
17	O
%	O
,	O
p=0.003	O
)	O
and	O
bother	O
(	O
52	O
%	O
vs.	O
15	O
%	O
,	O
P	O
=	O
0.002	O
)	O
from	O
baseline	O
to	O
1	O
year	O
.	O

In	O
contrast	O
to	O
those	O
on	O
active	O
surveillance	I:C1827061
,	O
more	O
than	O
half	O
the	O
number	O
of	O
patients	O
who	O
received	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
experienced	O
a	O
decline	O
in	O
bowel	B:C0011135
function	I:C0011135
(	O
52	O
%	O
vs.	O
17	O
%	O
,	O
p=0.003	O
)	O
and	O
bother	O
(	O
52	O
%	O
vs.	O
15	O
%	O
,	O
P	O
=	O
0.002	O
)	O
from	O
baseline	O
to	O
1	O
year	O
.	O

Patients	O
who	O
received	O
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
were	O
significantly	O
more	O
likely	O
to	O
experience	O
a	O
decrease	O
in	O
more	O
than	O
one	O
functional	O
domain	O
(	O
urinary	O
,	O
sexual	O
,	O
bowel	O
,	O
or	O
hormonal	O
)	O
at	O
1	O
year	O
when	O
compared	O
with	O
those	O
on	O
active	O
surveillance	I:C1827061
(	O
60	O
%	O
vs.	O
28	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Patients	O
who	O
received	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
were	O
significantly	O
more	O
likely	O
to	O
experience	O
a	O
decrease	O
in	O
more	O
than	O
one	O
functional	O
domain	O
(	O
urinary	O
,	O
sexual	B:C0009253
,	O
bowel	O
,	O
or	O
hormonal	O
)	O
at	O
1	O
year	O
when	O
compared	O
with	O
those	O
on	O
active	O
surveillance	I:C1827061
(	O
60	O
%	O
vs.	O
28	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Patients	O
who	O
received	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
were	O
significantly	O
more	O
likely	O
to	O
experience	O
a	O
decrease	O
in	O
more	O
than	O
one	O
functional	O
domain	O
(	O
urinary	O
,	O
sexual	O
,	O
bowel	B:C0021853
,	O
or	O
hormonal	O
)	O
at	O
1	O
year	O
when	O
compared	O
with	O
those	O
on	O
active	O
surveillance	I:C1827061
(	O
60	O
%	O
vs.	O
28	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Patients	O
who	O
received	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
were	O
significantly	O
more	O
likely	O
to	O
experience	O
a	O
decrease	O
in	O
more	O
than	O
one	O
functional	O
domain	O
(	O
urinary	O
,	O
sexual	O
,	O
bowel	O
,	O
or	O
hormonal	O
)	O
at	O
1	O
year	O
when	O
compared	O
with	O
those	O
on	O
active	B:C1827061
surveillance	I:C1827061
(	O
60	O
%	O
vs.	O
28	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Patients	O
receiving	O
external	B:C1517033
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
suffer	O
declines	O
in	O
bowel	O
HRQoL	O
.	O

Patients	O
receiving	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
for	O
low	O
-	O
risk	O
prostate	B:C0376358
cancer	I:C0376358
suffer	O
declines	O
in	O
bowel	O
HRQoL	O
.	O

Patients	O
receiving	O
external	O
-	I:C1517033
beam	I:C1517033
radiation	I:C1517033
therapy	I:C1517033
for	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
suffer	O
declines	O
in	O
bowel	B:C0021853
HRQoL	O
.	O

These	O
declines	O
are	O
not	O
experienced	O
by	O
patients	O
on	O
active	B:C1827061
surveillance	I:C1827061
,	O
suggesting	O
that	O
management	O
of	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
with	O
active	O
surveillance	I:C1827061
may	O
offer	O
a	O
means	O
for	O
preserving	O
HRQoL	O
following	O
prostate	O
cancer	I:C0376358
diagnosis	O
.	O

These	O
declines	O
are	O
not	O
experienced	O
by	O
patients	O
on	O
active	O
surveillance	I:C1827061
,	O
suggesting	O
that	O
management	O
of	O
low	O
-	O
risk	O
prostate	B:C0376358
cancer	I:C0376358
with	O
active	O
surveillance	I:C1827061
may	O
offer	O
a	O
means	O
for	O
preserving	O
HRQoL	O
following	O
prostate	O
cancer	I:C0376358
diagnosis	O
.	O

These	O
declines	O
are	O
not	O
experienced	O
by	O
patients	O
on	O
active	O
surveillance	I:C1827061
,	O
suggesting	O
that	O
management	O
of	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
with	O
active	B:C1827061
surveillance	I:C1827061
may	O
offer	O
a	O
means	O
for	O
preserving	O
HRQoL	O
following	O
prostate	O
cancer	I:C0376358
diagnosis	O
.	O

These	O
declines	O
are	O
not	O
experienced	O
by	O
patients	O
on	O
active	O
surveillance	I:C1827061
,	O
suggesting	O
that	O
management	O
of	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
with	O
active	O
surveillance	I:C1827061
may	O
offer	O
a	O
means	O
for	O
preserving	O
HRQoL	O
following	O
prostate	B:C0376358
cancer	I:C0376358
diagnosis	O
.	O

These	O
declines	O
are	O
not	O
experienced	O
by	O
patients	O
on	O
active	O
surveillance	I:C1827061
,	O
suggesting	O
that	O
management	O
of	O
low	O
-	O
risk	O
prostate	O
cancer	I:C0376358
with	O
active	O
surveillance	I:C1827061
may	O
offer	O
a	O
means	O
for	O
preserving	O
HRQoL	O
following	O
prostate	O
cancer	I:C0376358
diagnosis	B:C0011900
.	O

